Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)

Kamel Laribi; Stéphanie Poulain; Lise Willems; Fatiha Merabet; Charles Herbaux; Damien Roos-Weil; Inès Laribi de Materre; Xavier Roussel; Morgane Nudel; Sabine Tricot; Jehan Dupuis; Ronan Le Calloch; Benoit Bareau; Véronique Leblond

doi:10.1111/bjh.19409

Retour

Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)

Article de revue

Avec comité de lecture

Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)

Kamel Laribi, Stéphanie Poulain, Lise Willems, Fatiha Merabet, Charles Herbaux, Damien Roos-Weil, Inès Laribi de Materre, Xavier Roussel, Morgane Nudel, Sabine Tricot, …

British journal of haematology, Vol.204(6), pp.2233-2236

06/2024

DOI: https://doi.org/10.1111/bjh.19409

PMID: 38504454

Résumé

Aged

Aged, 80 and over

Antineoplastic Combined Chemotherapy Protocols - therapeutic use

Bendamustine Hydrochloride - administration & dosage

Bendamustine Hydrochloride - therapeutic use

Female

Follow-Up Studies

France

Humans

Male

Middle Aged

Rituximab - administration & dosage

Rituximab - therapeutic use

Treatment Outcome

Waldenstrom Macroglobulinemia - drug therapy

Waldenstrom Macroglobulinemia - mortality

The bendamustine-rituximab (BR) schedule is an efficient first-line therapy in Waldenström macroglobulinaemia (WM). A previous analysis of 69 patients who received this treatment confirmed a high response rate and good progression-free (PFS) and overall survival (OS). With a median follow-up of 76.1 months (95% confidence interval [CI] 69.9-80.6), 5-year outcome is still excellent at 66.63% (95% CI 56.09-79.17) for PFS and 80.01% (95% CI 70.82-90.41) for OS. The rate of secondary cancers is 17.66% (IQR 7.99-27.64) at 66 months. Relapsed patients who received ibrutinib as second-line clearly benefited from this schedule. This confirms current recommendations suggesting BR long-term efficacy as first-line option in WM.

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)
Créateurs - sans rôle: Kamel Laribi - Haematology Department, Le Mans Hospital, Le Mans, France
Stéphanie Poulain - Cellular Haematology, Biology and Pathology Center, Lille Regional and University Hospital and INSERM UMR 1172, IRCL, Lille, France
Lise Willems - Haematology Clinic, Cochin Hospital, APHP, Paris, France
Fatiha Merabet - Haematology and Oncology Clinic, André Mignot Hospital, Versailles Hospital, Versailles, France
Charles Herbaux - Haematology Clinic, Montpellier University Hospital, Montpellier, France
Damien Roos-Weil - Haematology Department, APHP, Sorbonne University, University Hospital La Pitié Salpêtrière-Charles Foix, Paris, France
Inès Laribi de Materre - Paris Centre University, Paris, France
Xavier Roussel - Haematology Department, University of Franche-Comté, INSERM UMR 1098, Besançon University Hospital, Besançon, France
Morgane Nudel - Haematology Department, Lille Regional and University Hospital, Lille, France
Sabine Tricot - Haematology Clinic, Valenciennes Hospital, Valenciennes, France
Jehan Dupuis - Lymphoid Malignancies Unit, APHP, Henri Mondor-Albert Chennevier Hospital, Créteil, France
Ronan Le Calloch - Internal Medicine, Infectiology and Blood Diseases, Cornouaille Hospital Center, Quimper, France
Benoit Bareau - Haematology and Internal Medicine Clinic, Sévigné Vivalto Santé Private Hospital, Cesson-Sévigné, France
Véronique Leblond - Haematology Department, APHP, Sorbonne University, University Hospital La Pitié Salpêtrière-Charles Foix, Paris, France
Détails de publication: British journal of haematology, Vol.204(6), pp.2233-2236
Identifiants: 99139710209311
Unité académique: Institut de Génétique Humaine - IGH
Langue: English
Type de ressource: Journal article